Report
Description
Report Description
Dengue is a mosquito-born flavivirus disease and causes dengue fever characterized by
severe headache, skin rash, debilitating muscle, joint pain leaving a feverish feeling. The
dengue virus is also called as ‘breakbone fever’ due to the symptoms it causes. The
symptoms for dengue start appearing in the span of 3-14 days and can infect infants,
young children and adults. Dengue has emerged as one of the critical vector-borne
diseases especially in tropical and subtropical regions of the world. The first dengue
vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur registered in Mexico in
December, 2015. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine
which was evaluated as a 3 dose series 0/6/12 month schedule in Phase III clinical
studies. There are around five other vaccine candidates under evaluation in clinical trials,
comprising other live-attenuated vaccines, as well as subunit, DNA and purified
inactivated vaccine candidates. Along with the developments in dengue vaccines
additional technological approaches, such as virus-vectored and VLP-based vaccines, are
held under evaluation in preclinical studies for further advancements.
The development for dengue vaccine had begun by 1929 but was delayed due to the
incomplete knowledge of the diseases. Sanofi Pasture first approved the vaccine for
dengue in 2015 and integrated dengue prevention reducing the mortality rate by almost
50%. WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYDTDV in April 2016 and recommended countries to introduce the vaccine through its
Global dengue prevention and Control Strategy (2012-2020).